SciSparc Ltd Dossier - Source-backed chat

SciSparc Ltd

SPRCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.94

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.55Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.6M

Enterprise Value $1.5M

Shares Outstanding 581K diluted

Next Earnings Date30 Apr 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. While the company has successfully regained conditional compliance with Nasdaq's minimum stockholders' equity requirement and is expanding its portfolio through strategic acquisitions—such as NeuroThera Labs' acquisition of CliniQuantum and the purchase of endoscopic IP from Xylo Technologies—it remains highly speculative. SciSparc continues to incur substantial net losses ($12.6 million in FY 2025) and has a limited cash runway, making its ability to continue as a going concern highly dependent on external financing and successful commercialization of its newly acquired assets.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0020%

The bear case is triggered if SciSparc fails to maintain Nasdaq listing compliance in its next periodic report, leading to delisting. Furthermore, if clinical trials face safety or efficacy setbacks, or if the company is unable to secure additional funding, the stock could face severe downward pressure and potential insolvency.

Base CaseCentral scenario

$7.5055%

The base case assumes SciSparc maintains its Nasdaq listing but continues to experience high cash burn and operational losses. Strategic acquisitions will take time to generate meaningful revenue, and the company will likely require further dilutive equity raises to sustain its clinical programs, keeping the stock range-bound.

Bull CaseUpside scenario

$12.0025%

The bull case relies on the rapid commercialization of the newly acquired endoscopic IP portfolio (including the MUSE system for GERD) and successful clinical milestones for lead drug candidates SCI-110 and SCI-210. Additionally, the integration of CliniQuantum's quantum-simulation platform could significantly accelerate drug discovery and clinical trial modeling, attracting lucrative pharmaceutical partnerships.

Scenarios reflect our research view at the research date.

Key Investment Merits

Diversified IP portfolio spanning cannabinoid therapies, quantum-based clinical trial modeling, and endoscopic medical devices.
Regained conditional compliance with Nasdaq listing standards as of May 2026.
Strategic collaborations, such as the joint patent applications with Clearmind Medicine, targeting high-value markets like weight loss and depression.

Key Investment Risks

History of substantial net losses ($12.6 million in FY 2025) and accumulated deficit of approximately $87 million.
Going concern risk with current cash reserves insufficient to fund planned operations for a full year without additional financing.
High dilution risk from frequent equity offerings, convertible notes, and reverse share splits (such as the 1-for-9 split in March 2026).

Thesis Invalidation Triggers

Delisting from the Nasdaq Capital Market due to future non-compliance with listing rules.
Failure to close or successfully integrate key acquisitions like CliniQuantum.
Negative clinical trial readouts or regulatory rejections for lead drug candidates.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.